In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...
A U.S. appeals court on Tuesday overturned a nearly $42 million jury verdict won by Pfizer's Seagen against Japanese rival ...
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...
Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...
Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...
Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...
Clinical Trials Arena on MSN
Daiichi Sankyo announces first patient dosed in phase III trial of Enhertu
Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...
AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...
The Federal Circuit wiped out biotech company Seagen Inc.'s $41.8 million verdict against AstraZeneca Pharmaceuticals LP and ...
The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback